Nova Mentis

Nova Mentis is a Canadian listed (CSE, FSE) company that holds two subsidiaries, Nova Mentis Biotech and Pilz BioSciences that investigate psychedelics as medicines for a variety of mental health indicators.

Nova Mentis

Nova Mentis Biosciences is focused on obesity, diabetes, and liver disease (NASH).

Pilz Biosciences is working on Autism Spectrum Disorder (ASD), for which they have launched a clinical study in May 2021.

The company was formally named Liberty Leaf Holdings (with a focus on the cannabis market).

Nova Mentis is listed on the CNSX under the ticker NOVA.

We’re a Canadian-based biotechnology company and global leader in psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders. Our mission is to diagnose and treat debilitating chronic conditions that have unmet medical needs, such as autism spectrum disorder and fragile X syndrome.

Company Information

Nova Mentis Website

January, 1970


B2B B2C Pharmaceutical Biotech

Topics of Interest

Explore more company info with a Tree membership

📰 Weekly newsletter about the business of psychedelics
📈 Extended company information (analyst view, fundraising, revenue numbers)
🪄 Priority company page updates

Explore memberships


HQ / Office 838 W Hastings St # 700, Vancouver, BC V6C 0A6, Canada
Inline Feedbacks
View all comments